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Novelty and impact of the paper  
 
Women who test high-risk HPV-positive require follow-up testing to avoid over-
diagnosis and over-treatment. This paper is the first to compare the clinical performance 
of FAM19A4 methylation analysis for the detection of cervical (pre)cancer to cytology 
and HPV16/18 genotyping in a prospective observational multi-center cohort study in a 
hrHPV-positive gynecological outpatient population. Performance of methylation 
analysis to detect high-grade disease was dependent on age. Among hrHPV-positive 
women aged ≥30 years, methylation analysis appeared a valuable alternative to 
cytology and HPV16/18 genotyping. 
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ABSTRACT 
Recently, DNA methylation analysis of FAM19A4 in cervical scrapes has been shown to 
adequately detect high-grade cervical intraepithelial neoplasia and cervical cancer 
(≥CIN3) in high-risk HPV (hrHPV)-positive women. Here, we compared the clinical 
performance of FAM19A4 methylation analysis to cytology and HPV16/18 genotyping, 
separately and in combination, for ≥CIN3 detection in hrHPV-positive women 
participating in a prospective observational multi-center cohort study. The study 
population comprised hrHPV-positive women aged 18-66 years, visiting a gynecological 
outpatient clinic. From these women, cervical scrapes and colposcopy-directed biopsies 
(for histological confirmation) were obtained. Cervical scrapes were analyzed for 
FAM19A4 gene promoter methylation, cytology and HPV16/18 genotyping. Methylation 
analysis was performed by quantitative methylation-specific PCR (qMSP). Sensitivities 
and specificities for ≥CIN3 were compared between tests. Stratified analyses were 
performed for variables that potentially influence marker performance. Of all 508 hrHPV-
positive women, the sensitivities for ≥CIN3 of cytology, FAM19A4 methylation analysis, 
and cytology combined with HPV16/18 genotyping were 85.6%, 75.6% and 92.2%, 
respectively, with corresponding specificities of 49.8%, 71.1%, and 29.4%, respectively. 
Both sensitivity and specificity of FAM19A4 methylation analysis were associated with 
age (p≤0.001 each). In women ≥30 years (n=287), ≥CIN3 sensitivity of FAM19A4 
methylation analysis was 88.3% (95%CI:80.2-96.5) which was non-inferior to that of 
cytology [85.5% (95%CI:76.0-94.0)], at a significantly higher specificity [62.1% 
(95%CI:55.8-68.4) compared to 47.6% (95%CI:41.1-54.1)]. In conclusion, among 
hrHPV-positive women from an outpatient population aged ≥30 years, methylation 
analysis of FAM19A4 is an attractive marker for the identification of women with ≥CIN3. 
 
3 
 
INTRODUCTION  
An infection with high-risk human papillomavirus (hrHPV) is essential for the 
development of cervical cancer1,2. HrHPV DNA testing has emerged as a more sensitive 
screening tool than cytology, leading to a higher protection against cervical 
intraepithelial neoplasia grade 3 (CIN3) and cervical cancer3–5. However, many hrHPV 
infections have an indolent nature and only a fraction of hrHPV-positive women have 
high-grade CIN lesions with a high cancer progression risk. In order to reduce over-
diagnosis and unnecessary referral, additional triage testing is required to detect the 
subgroup of hrHPV-positive women with clinically meaningful cervical disease. To date, 
various triage strategies for hrHPV-positive women have been considered including 
repeat cytology testing6, HPV E7 mRNA analysis7,8, p16/ki67 cytological dual 
staining9,10, HPV16/18 genotyping11,12, and combinations thereof6,13. Besides these 
markers, epigenetic changes in the host and/or viral genome that are associated with 
progression towards invasive cancer1,14 are attractive targets to design objective and 
molecular biomarkers to detect amongst hrHPV-positive women those who have 
cervical (pre)cancer. DNA methylation analysis of human genes by (quantitative) 
methylation-specific PCR (MSP)-based methods has shown promising results on both 
hrHPV-positive cervical scrapes and self-collected specimens15–20, with overall 
sensitivities for ≥CIN3 similar to those of cytology, and extremely high sensitivities (up to 
100%) for cervical carcinoma16,18,21. When applied to cervical scrapes, a methylation 
marker recently identified by a genome-wide methylation screen, FAM19A422, was 
shown to detect all cervical carcinomas and CIN3 lesions with a long-term (i.e., ≥5 
years) duration of preceding hrHPV-infection (PHI, used as a proxy of duration of lesion 
existence)23. The latter are considered the more advanced CIN3 lesions with a high 
short-term progression risk to cancer, partially explained by a high number of 
chromosomal alterations24. As such, FAM19A4 can be an attractive marker for cervical 
disease in hrHPV-positive women. In this prospective cohort study, performed on 
hrHPV-positive women from six outpatient clinics, we compared the clinical 
performance of FAM19A4 methylation analysis to cytology and HPV16/18 genotyping, 
separately and in combination, for the detection of CIN3 or cervical cancer (≥CIN3).  
 
MATERIALS AND METHODS  
Study design, participants, and procedures 
From December 2010 till December 2013, women between 18 and 70 years were 
recruited for participation in a prospective observational multi-center cohort study 
among women visiting a gynecological outpatient clinic in one of six hospitals in the 
Netherlands: VU University Medical Center (VUmc), Sint Lucas Andreas Hospital, 
University Medical Center Utrecht, Reinier de Graaf Groep, Sint Antonius Hospital and 
Flevo Hospital. The study was approved by the Medical Ethical Committee of all 
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participating hospitals (METc-VUmc2009/178) and registered as NTR2447. Women 
were eligible for participation in the study regardless of their reason for visiting the 
gynecologist. Consequently, also women who had been referred because of a recent 
abnormal cervical scrape could participate. Exclusion criteria included any history of 
treatment for cervical dysplasia or cervical cancer, current cancer, pregnancy or 
lactation. As shown in Figure 1, in total 2970 women gave informed consent and 
participated in the study. These women were offered self-sampling of cervico-vaginal 
lavage material using the Delphi screener (Delphi Bioscience, the Netherlands) for 
hrHPV testing using GP5+/6+ PCR-enzyme immunoassay analysis (EIA kit HPV GP 
HR, Diassay B.V., the Netherlands)18. All self-sample analyses were performed at the 
department of Pathology at VUmc. From 717 women who tested hrHPV-positive on self-
collected material, 78 (11%) had to be excluded as they did not meet the inclusion 
criteria. From the remaining 639 women, a cervical scrape was taken by the 
gynecologist using a Cervex-Brush (Rovers Medical Devices B.V., the Netherlands) or a 
Medscand Cytobrush Plus (CooperSurgical Inc., USA). Material was stored in 20 ml of 
Thinprep PreservCyt solution (Hologic, USA). Cervical scrapes that tested hrHPV-
positive (n=556) were subsequently tested for three markers: (liquid based) cytology, 
FAM19A4 methylation and HPV16/18 genotyping. Women with valid test results in all 
three assays (n=508) comprised the final study population and all underwent 
colposcopy-examination. In 289 (57%) women, the cervical scrape was taken at a 
separate visit, at a minimum of two weeks prior to colposcopy. In 219 (43%) women, for 
logistic reasons, the cervical scrape was done immediately prior to colposcopy.  
At colposcopy, cervical biopsies were taken from every visible lesion for histological 
assessment and classified as normal (CIN0), CIN1, CIN2, CIN3, or invasive cancer, 
according to international criteria. In case no lesions were visible, it was mandatory to 
take two random biopsies (6 and 12 o’ clock). In case the squamocolumnar junction 
could not be brought into view, endocervical curettage was performed. All women were 
treated according to national guidelines for CIN and cervical cancer. All women with 
histologically confirmed CIN3 underwent large loop excision of the transformation zone 
(LLETZ) or cervical conisation. Depending on the size of the lesion, also 65% (i.e., 
65/100) of women with CIN2 underwent LLETZ. Of these, 10 (15%) were diagnosed 
with CIN3 in the LLETZ tissue, and categorized accordingly.  
Cytology  
Liquid based cytology preparations were cytologically classified according to the 
CISOE-A classification (reporting on composition, inflammation, squamous, other and 
endometrium, and endocervical cylindrical epithelium, and adequacy) used in the 
Netherlands. The results can be translated into the Bethesda classification25, in which 
borderline or mild dyskaryosis (BMD) equals ASC-US/ASC-H/LSIL, and >BMD equals 
high-grade squamous intraepithelial lesion (HSIL). Cytotechnicians were aware of the 
hrHPV-positive status of the cervical scrapes. 
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HPV genotyping 
DNA was isolated from 1/10th of cervical scrape material using the Nucleo-Spin 96 
Tissue kit (Macherey-Nagel, Germany) and a Microlab Star robotic system (Hamilton, 
Germany) according to manufacturers’ instructions16, and subjected to GP5+/6+PCR-
EIA. Subsequent genotyping for the high-risk HPV types 
16/18/31/33/35/39/45/51/52/56/58/59/66/68 was performed using a microsphere bead-
based assay (Luminex) as previously described26.  
qMSP analysis 
Extracted DNA from hrHPV-positive cervical scrapes was subjected to bisulphite 
treatment using the EZ DNA Methylation Kit (Zymo Research, USA) as described 
previously27,28. Bisulphite-converted DNA was used as template for FAM19A4 
methylation analysis by qMSP using housekeeping gene β-actin (ACTB) as a reference 
gene22,23. qMSP analysis was performed on an ABI 7500 real-time PCR-system 
(Applied Biosystems, USA). For each target, Quantification Cycle (Cq) values were 
measured at a fixed fluorescence threshold. All samples included in the study had a Cq 
value for ACTB <32 to assure sample quality. For each sample Cq ratios were 
calculated using the following formula: 2[Cq (ACTB) - Ct (FAM19A4)] x100. The threshold value 
(0.415) that gave rise to a ≥CIN3 specificity of 70%, as determined and validated in De 
Strooper et al.23, was chosen to consider a specimen positive for FAM19A4 methylation.  
Statistical analysis  
We used histologically confirmed ≥CIN3 as primary study endpoint. ≥CIN2 was used as 
secondary study endpoint, as the category of CIN2 reflects heterogeneous disease, of 
which a substantial portion represent productive hrHPV-infections1 that will regress 
spontaneously29,30. Study endpoint was assessed based on the histological outcome of 
the colposcopy-directed biopsy, or, if classified worse, on the histology result of the 
specimen excised by LLETZ, conisation or uterus extirpation. The sample size was set 
such that 90% power was achieved for demonstrating non-inferiority of FAM19A4 
methylation analysis or HPV16/18 genotyping compared to cytology using a matched-
sample score test31,32. A minimum of 300 hrHPV-positive women needed to be included 
at rejection rate α of 0.05. Finally, 508 hrHPV-positive women were included with results 
for all markers. For FAM19A4 methylation analysis, cytology, HPV16/18 genotyping and 
combinations (i.e., FAM19A4 and cytology, FAM19A4 and HPV16/18 genotyping, 
HPV16/18 genotyping and cytology), sensitivity, specificity, positive predictive value 
(PPV), 1-negative predictive value (complemented NPV, a measure of disease risk after 
a negative result) for detection of ≥CIN3 and ≥CIN2 and referral rate (based on % 
marker positivity) were calculated with 95% confidence intervals (95% CI). Relative 
sensitivities (ratios of the sensitivity of one test to the sensitivity of another test) and 
relative specificities (ratios of the specificity of one test to the specificity of another test) 
were calculated with 95% CIs to enable comparisons. A difference in sensitivity or 
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specificity was considered significant if the 95%CI of the relative sensitivity or specificity 
was entirely below or above one. Forest plots of relative sensitivities and specificities of 
the different tests were made using cytology as reference test. In case of non-significant 
differences in sensitivity, an additional non-inferiority test was performed. Non-inferiority 
was defined as a relative sensitivity of at least 90% using a matched-sample score 
test31,32.  
We considered the influence of three factors when estimating the sensitivity and 
specificity of the different markers. First, the age of the participants (aged ≥30 years 
(cervical screening target in the Netherlands) versus <30 years); secondly, the reason 
of referral to the gynecologist (non-cervix-related gynecological complaints versus a 
recent abnormal cytology result in cervical screening); and thirdly, the sampling method 
of the cervical scrape (whether the collection of the cervical scrape was done during a 
separate visit prior to colposcopy versus cervical scrape combined with the colposcopy 
procedure in one visit). The influence of the factors was studied using logistic 
regression. After determining the factors that significantly influenced the performance of 
the different markers (significance: p<0.05), data were stratified for these factors. All 
statistical analyses and computation of graphs were performed in IBM SPSS Statistics 
20, STATA 11.0 and Excel. 
 
RESULTS 
Patients and histological outcomes 
The study flowchart is shown in Figure 1. Final analysis comprised 508 women who had 
valid results for all three markers and who underwent colposcopy-examination. 
Histology revealed that three women (0.6%) had invasive cervical carcinoma (i.e., one 
squamous cell carcinoma (SCC), one adenosquamous carcinoma and one 
adenocarcinoma (AdCA)), 87 women (17.1%) had CIN3 (including 2 adenocarinoma in 
situ), 90 women (17.7%) had CIN2, 138 (27.2%) had CIN1 and 190 (37.4%) had no 
CIN. Of the corresponding 508 hrHPV-positive cervical scrapes, 37% (189/508) scored 
positive for FAM19A4 methylation, 56% (287/508) had abnormal cytology (≥BMD) and 
48% (243/508) tested positive for HPV16 and/or HPV18 (HPV16/18). All three women 
diagnosed with cervical cancer tested positive for both FAM19A4 methylation and 
cytology. Two of them scored HPV16 positive, and one woman with SCC had a single 
infection with HPV39. 
Performance of markers 
Test specifications of the investigated markers, and combinations thereof, for detection 
of ≥CIN3 in the total study population are shown in Table 1 (upper panel). Relative 
sensitivities and specificities for ≥CIN3 of FAM19A4 methylation analysis, HPV16/18 
genotyping, and various marker combinations compared to cytology (which was used as 
reference), are shown in Figure 2 (upper panel). The ≥CIN3 sensitivity of FAM19A4 
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methylation analysis (75.6%) and cytology (85.6%) did not differ significantly. As a 
statistical difference between the sensitivities of both markers could not be established, 
subsequent matched sample score testing was performed to evaluate non-inferiority. As 
the relative sensitivity of FAM19A4 methylation analysis was lower than 90%, the non-
inferiority threshold was not met (p=0.61). The ≥CIN3 specificity (71.1%) of FAM19A4 
methylation analysis was significantly higher than that of cytology (49.8%). For ≥CIN2 
outcome (Table 2 and Figure 3, upper panel), a significantly lower sensitivity of 
FAM19A4 methylation analysis (57.8%) compared to cytology (82.8%) was observed at 
a significantly higher specificity (74.1% versus 57.9%). In addition, the ≥CIN3 sensitivity 
of FAM19A4 methylation analysis was significantly lower than that of cytology combined 
with HPV16/18 genotyping (75.6% versus 92.2%; ratio 0.82; 95%CI:0.72-0.93), at 
significantly higher specificity (71.1% versus 29.4%; ratio 2.41; 95%CI:2.07-2.82). 
Similar results were obtained for ≥CIN2 detection (FAM19A4 methylation analysis 
versus cytology and HPV16/18 testing: sensitivity 57.8% versus 89.4%; ratio 0.65; 
95%CI:0.57-0.74; specificity 74.1% versus 33.8%; ratio 2.19; 95%CI:1.86-2.57; Table 
2). The ≥CIN3 sensitivity of FAM19A4 methylation analysis combined with cytology was 
significantly higher than that of cytology alone (94.4% versus 85.6%), but had a 
significantly lower specificity (37.8% versus 49.8%; Table 1; Figure 2). The ≥CIN3 
sensitivity of combined FAM19A4 methylation analysis and HPV16/18 genotyping was 
non-inferior to cytology (92.2% versus 85.6%; p<0.001) but had a significantly lower 
specificity (42.3% versus 49.8%; Table 1; Figure 2).  
Factors influencing marker performance 
Three factors were evaluated for a potential influence on marker performance: 1) age of 
the participants , i.e., women ≥30 years (n=287) or <30 years (n=221); 2) reason of 
referral, i.e., because of a recent abnormal cytological scrape (n=213) or non-cervix-
related gynecological complaints (n=295), 3) moment of taking cervical scrape, i.e., at a 
separate visit 2-3 weeks prior to the colposcopy visit (n=289) or at the same visit as 
colposcopy (n=219). The performance of FAM19A4 methylation analysis was 
significantly influenced by age of the participants (Table 3A), whereas the performance 
of cytology was significantly correlated to the referral reason to the gynecologist, both in 
univariate and multivariate analyses (Table 3B). The performance of HPV16/18 
genotyping was not influenced by any of these variables (data not shown). The moment 
of taking the cervical scrape did not influence the performance of the investigated  
markers. 
Stratified analysis of marker performance 
Subsequently, marker analysis was performed after stratification for age (for FAM19A4 
methylation analysis) and referral reason (for cytology). Of note, in women <30 years, 
31% was referred based on non-cervix-related complaints whereas in women ≥30 years 
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56% was referred with an abnormal scrape. The performance of the markers in the 
subpopulation of women ≥30 years for the detection of ≥CIN3 (n=287; 60 ≥CIN3, 51 
CIN2 and 176 ≤CIN1), the age group targeted in Dutch national screening, are shown in 
Table 1 and Figure 2 (lower panel). In this subpopulation, the ≥CIN3 sensitivity of 
FAM19A4 methylation analysis (88.3%) was non-inferior (p=0.024) to that of cytology 
(85.0%), whereas its specificity was significantly higher (62.1% versus 47.6%). Results 
for ≥CIN2 are presented in Figure 3 and Table 2. In the subgroup of women <30 years 
(n=221; 30 ≥CIN3, 39 CIN2 and 152 ≤CIN1), the ≥CIN3 sensitivity of FAM19A4 
methylation analysis was significantly lower compared to that of cytology (50.0% versus 
86.7%; ratio 0.58; 95%CI:0.40-0.83; Table 1), whereas its specificity was significantly 
higher (81.7% versus 52.4%; ratio 1.56; 95%CI:1.35-1.80; Table 1). In the 
subpopulation of women referred to the gynecologist because of non-cervix-related 
gynecological complaints (n=295; 26 ≥CIN3, 43 CIN2 and 226 ≤CIN1), the ≥CIN3 
sensitivity of FAM19A4 methylation analysis did not differ significantly from cytology 
(61.5% versus 80.8%; ratio 0.76; 95%CI:0.55-1.05). Subsequent matched sample score 
testing was performed to evaluate non-inferiority, which could not be established 
(p=0.85). The specificity of FAM19A4 methylation analysis was significantly higher than 
that of cytology (73.2% versus 63.6%; ratio 1.15; 95%CI:1.03-1.28). Results for ≥CIN2 
are presented in Table 2. 
 
DISCUSSION 
This prospective multi-center cohort study shows that molecular analysis of FAM19A4 
methylation is non-inferior to cytology with respect to sensitivity for ≥CIN3 (88.3% 
versus 85.0%) in hrHPV-positive women from an outpatient population, aged ≥30 years, 
at a significantly higher specificity (62.1% versus 47.6%), In women <30 years, an age 
category known to often harbor transient hrHPV infections33,34, FAM19A4 methylation 
analysis had a poor ≥CIN3 sensitivity compared to cytology (50% versus 86.7%), but 
had a significantly higher specificity (81.7% versus 52.4%).  
To our knowledge, this study is the first to compare the clinical features of FAM19A4 
methylation analysis to those of other commonly used tests for detecting cervical disease in a 
large cohort of women with hrHPV-positive cervical scrapes. Even under the setting of potential 
cytology bias, given that a part of women were included with a previously abnormal cytology 
test, the sensitivity of FAM19A4 methylation analysis reached non-inferiority to cytology in 
hrHPV-positive women aged ≥30 years. In notice of a cytology bias, we included in our study a 
subgroup analysis of women who visited the outpatient clinic for non-cervix-related complaints,  
in which ≥CIN3 sensitivity of FAM19A4 methylation analysis also did not differ significantly from 
cytology (61.5% versus 80.8%; ratio 0.76; 95%CI:0.55-1.05), although non-inferiority could not 
be established. In a subgroup analysis comprising HPV-positive women with normal cytology 
≥30 years of age (data not shown), FAM19A4 methylation analysis reached a ≥CIN3 sensitivity 
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of 77.8 (7/9; 95%CI: 50.6-100%) at 67.6% specificity (73/108; 95%CI: 58.8-76.4%). Despite the 
fact that data are based on relatively low numbers, these findings illustrate the value of 
FAM19A4 methylation analysis for HPV-positive women with normal cytology. 
Previous research has outlined the high sensitivity of DNA methylation analysis for 
detecting CIN3 lesions with a long duration of existence (so-called advanced CIN3 
which are expected to have a high short-term risk of progression to cancer) and cervical 
carcinoma23,35, in contrast to cytology1,15,23,36. In the present study, 50/57 (87.8%) 
women ≥30 years with CIN3 lesions tested positive by FAM19A4 methylation analysis 
and 48/57 (84.2%) by cytology. On the other hand, only 26/51 (51%) women with CIN2 
were positive by FAM19A4 methylation analysis, whereas 45/54 (88.2%) of these 
women tested positive for cytology. These data underscore that a positive FAM19A4 
methylation result is more likely to represent underlying CIN3 than CIN2, whereas 
cytology, in this outpatient population, has high sensitivities for both CIN2 and CIN3.  
The overall high sensitivity of cytology in this cohort might be explained by the presence 
of cytology bias in this referral population and/or the prior knowledge of the HPV status 
of the scrapes at cytology reading. This probably results in easier classification of 
abnormal cytology37,38. In an HPV-based screening program, only hrHPV-positive 
women will be triaged by cytology, so it is important to stay alert for potential over-
referral. FAM19A4 methylation analysis can therefore be an adequate alternative triage 
method, with a negative test result providing high reassurance of absence of advanced 
cervical disease and cancer23. Furthermore, as large variation exists in the quality of 
cytological screening amongst different countries, a more objective triage strategy of 
hrHPV-positive women in the future is preferable39.  
Among many previously described methylation markers1,40, FAM19A4 has shown to 
efficiently detect virtually all cervical carcinomas and advanced CIN3 lesions23. In pilot 
studies, FAM19A4 methylation analysis appeared to perform well on cervical scrapes, 
which had been collected immediately prior to colposcopy. This is remarkable, as this 
sampling procedure has been shown to compromise performance of a previously 
validated methylation marker panel, i.e., CADM1/MAL, in a cross-sectional cohort41. The 
decrease in marker performance was likely related to more cautious brushing of the 
cervix (to prevent bleeding) and therefore lower abnormal cell counts in the resulting 
cervical scrapes41. In the current study, we found that the clinical performance of 
FAM19A4 methylation was not influenced by the sampling method of the cervical 
scrape (whether it was collected in a separate event or immediately prior to 
colposcopy). 
Another important finding of our research was the significant influence of age on 
FAM19A4 methylation positivity. This finding is in line with Hansel et al.42, who have 
described the detection of only 5/14 ≥CIN3 in women <30 years versus 8/9 ≥CIN3 in 
women ≥30 years using a methylation five-marker panel. However, Hesselink et al.16 did 
not find a correlation of methylation with age using a bi-marker panel. The latter might 
10 
 
be explained by the limited number of women <30 years included in that study. Our 
study included 287 women <30 years, giving a more representative view on the 
correlation between age and DNA methylation in detection of ≥CIN2/3. Although hrHPV 
prevalence in young women is known to be high, most infections are transient and most 
lesions regress spontaneously34,43,44, contributing to a very low cancer incidence in this 
age group45. Screening these young women by cytology would lead to high ≥CIN2/3 
sensitivities, yet likely at the cost of detecting many regressing CIN2 and a number of 
early CIN3 lesions, leading to significant over-referral and -treatment. Although testing 
hrHPV-positive young women by FAM19A4 methylation analysis would result in a lower 
sensitivity for ≥CIN2/3 than cytology, it likely reassures against advanced CIN lesions 
and cervical cancer at a substantially higher specificity. If validated in an independent 
study, this hypothesis may form the basis of an interesting management strategy for 
young hrHPV-positive women visiting a gynecological outpatient clinic, given possible 
treatment morbidity such as cervical insufficiency, and associated risk for pre-term 
delivery46–48.  
The broad age range of the population provides insight in the performance of this 
molecular marker in younger women. A limitation of our study might be that the age 
categorization used in this study (≥30 years versus <30 years) is based on the starting 
age at which women in the Netherlands are invited for cervical screening (i.e., 30 
years). However, several Western countries start screening at an earlier age. In the 
USA, the FDA has approved an HPV test for use as a first-line primary cervical cancer 
screening test for women of ≥25 years49,50. Interestingly, in hrHPV-positive women in 
the age category ≥25 years (Supplementary Figure 1), the performance of FAM19A4 
methylation analysis was similar to the performance in women aged ≥30 years.  
Due to the selection of an outpatient population, one has to realize that the translation of 
our results into screening settings should be handled with care. Furthermore, the fact 
that 8% of FAM19A4 methylation analyses yielded an invalid test result is relevant. We 
found that the majority (89.5%) of these invalid tests were done on cervical scrapes 
taken directly prior to colposcopy. As mentioned above, more cautious scraping by the 
physician (to ascertain adequate colposcopic imaging) may have resulted in insufficient 
cell numbers in these cervical scrapes, and associated low DNA concentrations, which 
may contribute to invalid test results.  
In conclusion, this study showed that promoter methylation analysis of FAM19A4 is an 
objective, molecular marker that performs at least non-inferior to cytology for the 
detection of ≥CIN3 lesions in hrHPV-positive cervical scrapes from a gynecological 
outpatient population (aged ≥30 years) at a significantly higher specificity.  
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TABLES 
 
Table 1. Test specifications of cytology, FAM19A4 methylation analysis, HPV16/18 genotyping and combinations of 
markers for detection of ≥CIN3 in hrHPV-positive women in the total study population, and stratified by age and referral 
reason.  
 
Triage marker Sensitivity Specificity PPV 1-NPV Referral rate*
Total study population (n=508)
Cytology 77 / 90 85.6% ( 78.3% - 92.8% ) 208 / 418 49.8% ( 45.0% -54.6% ) 26.8% ( 21.7% - 32.0% ) 5.9% ( 2.8% - 9.0% ) 56.5%
FAM19A4 methylation 68 / 90 75.6% ( 66.7% - 84.4% ) 297 / 418 71.1% ( 66.7% -75.4% ) 36.0% ( 29.1% - 42.8% ) 6.9% ( 4.1% - 9.7% ) 37.2%
HPV16/18 genotyping 65 / 90 72.2% ( 63.0% - 81.5% ) 307 / 418 57.4% ( 52.7% -62.2% ) 26.7% ( 21.2% - 32.3% ) 9.4% ( 5.9% - 13.0% ) 47.8%
FAM19A4  methylation and/or cytology 85 / 90 94.4% ( 89.7% - 99.2% ) 158 / 418 37.8% ( 33.2% -42.4% ) 24.6% ( 20.1% - 29.2% ) 3.1% ( 0.4% - 5.7% ) 67.9%
FAM19A4  methylation and/or HPV16/18 genotyping 83 / 90 92.2% ( 86.7% - 97.8% ) 177 / 418 42.3% ( 37.6% -47.1% ) 25.6% ( 20.9% - 30.4% ) 3.8% ( 1.0% - 6.6% ) 63.8%
Cytology and/or HPV16/18 genotyping 83 / 90 92.2% ( 86.7% - 97.8% ) 123 / 418 29.4% ( 25.1% -33.8% ) 22.0% ( 17.8% - 26.1% ) 5.4% ( 1.5% - 9.3% ) 74.4%
Subgroup: women <30 years (n=221)
Cytology 26 / 30 86.7% ( 74.5% - 98.8% ) 100 / 191 52.4% ( 45.3% -59.4% ) 22.2% ( 14.7% - 29.8% ) 3.8% ( 0.2% - 7.5% ) 52.9%
FAM19A4 methylation 15 / 30 50.0% ( 32.1% - 67.9% ) 156 / 191 81.7% ( 76.2% -87.2% ) 30.0% ( 17.3% - 42.7% ) 8.8% ( 4.5% - 13.0% ) 22.6%
HPV16/18 genotyping 23 / 30 76.7% ( 61.5% - 91.8% ) 109 / 191 57.1% ( 50.0% -64.1% ) 21.9% ( 14.0% - 29.8% ) 6.0% ( 1.7% - 10.4% ) 47.5%
FAM19A4  methylation and/or cytology 27 / 30 90.0% ( 79.3% - 100.0% ) 85 / 191 44.5% ( 37.5% -51.6% ) 20.3% ( 13.5% - 27.1% ) 3.4% ( 0.0% - 7.2% ) 60.2%
FAM19A4  methylation and/or HPV16/18 genotyping 27 / 30 90.0% ( 79.3% - 100.0% ) 93 / 191 48.7% ( 41.6% -55.8% ) 21.6% ( 14.4% - 28.8% ) 3.1% ( 0.0% - 6.6% ) 56.6%
Cytology and/or HPV16/18 genotyping 29 / 30 96.7% ( 90.2% - 100.0% ) 59 / 191 30.9% ( 24.3% -37.4% ) 18.0% ( 12.1% - 23.9% ) 1.7% ( 0.0% - 4.9% ) 72.9%
Subgroup: women ≥30 years (n=287)
Cytology 51 / 60 85.0% ( 76.0% - 94.0% ) 108 / 227 47.6% ( 41.1% -54.1% ) 30.0% ( 23.1% - 36.9% ) 7.7% ( 2.9% - 12.5% ) 59.2%
FAM19A4 methylation 53 / 60 88.3% ( 80.2% - 96.5% ) 141 / 227 62.1% ( 55.8% -68.4% ) 38.1% ( 30.1% - 46.2% ) 4.7% ( 1.3% - 8.1% ) 48.4%
HPV16/18 genotyping 42 / 60 70.0% ( 58.4% - 81.6% ) 131 / 227 57.7% ( 51.3% -64.1% ) 30.4% ( 22.8% - 38.1% ) 12.1% ( 6.8% - 12.1% ) 48.1%
FAM19A4  methylation and/or cytology 58 / 60 96.7% ( 92.1% - 100.0% ) 73 / 227 32.2% ( 26.1% -38.2% ) 27.4% ( 21.4% - 33.4% ) 2.7% ( 0.0% - 6.3% ) 73.9%
FAM19A4  methylation and/or HPV16/18 genotyping 56 / 60 93.3% ( 87.0% - 99.6% ) 84 / 227 37.0% ( 30.7% -43.3% ) 28.1% ( 21.9% - 34.4% ) 4.5% ( 0.2% - 8.9% ) 69.3%
Cytology and/or HPV16/18 genotyping 54 / 60 90.0% ( 82.4% - 97.6% ) 64 / 227 28.2% ( 22.3% -34.0% ) 24.9% ( 19.1% - 30.6% ) 8.6% ( 2.0% - 15.1% ) 75.6%
Subgroup: women referred to gynecologist for non-cervix related complaints (n=295)
Cytology 21 / 26 80.8% ( 65.6% - 95.9% ) 171 / 269 63.6% ( 57.8% -69.3% ) 17.6% ( 10.8% - 24.5% ) 2.8% ( 0.4% - 5.3% ) 40.3%
FAM19A4 methylation 16 / 26 61.5% ( 42.8% - 80.2% ) 197 / 269 73.2% ( 67.9% -78.5% ) 18.2% ( 10.1% - 26.2% ) 4.8% ( 1.9% - 7.8% ) 29.8%
HPV16/18 genotyping 20 / 26 76.9% ( 60.7% - 93.1% ) 154 / 269 57.2% ( 51.3% -63.2% ) 14.8% ( 8.8% - 20.8% ) 3.8% ( 0.8% - 6.7% ) 45.8%
FAM19A4  methylation and/or cytology 23 / 26 88.5% ( 76.2% - 100.0% ) 133 / 269 49.4% ( 43.5% -55.4% ) 14.5% ( 9.0% - 19.9% ) 2.2% ( 0.0% - 4.7% ) 53.9%
FAM19A4  methylation and/or HPV16/18 genotyping 23 / 26 88.5% ( 76.2% - 100.0% ) 120 / 269 44.6% ( 38.7% -50.6% ) 13.4% ( 8.3% - 19.9% ) 2.4% ( 0.0% - 5.2% ) 58.3%
Cytology and/or HPV16/18 genotyping 24 / 26 92.3% ( 82.1% - 100.0% ) 101 / 269 37.5% ( 31.8% -43.3% ) 12.5% ( 7.8% - 17.2% ) 1.9% ( 0.0% - 4.6% ) 65.1%
(95%CI) (95%CI)
CIN=cervical intraepithelial neoplasia (grade 2 or 3 or higher); CI=confidence interval; PPV=positive predictive value; 1-NPV= complemented negative predictive value; n1= number of test positive disease cases; N1= total number of disease cases; n2= 
number of test negative non-disease cases; N2= total number of non-disease cases; *based on % marker positivity
n1 / N1 n2 / N2 (95%CI)(95% CI)
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Table 2. Test specifications of cytology, FAM19A4 methylation analysis, HPV16/18 genotyping and combinations of 
markers for detection of ≥CIN2 in hrHPV-positive women in the total study population, and stratified by age and referral 
reason. 
Triage marker Sensitivity Specificity PPV 1-NPV Referral rate*
Total study population (n=508)
Cytology 149 / 180 82.8% ( 77.3% - 88.3% ) 190 / 328 57.9% ( 52.6% - 63.3% ) 51.9% ( 46.1% - 57.7% ) 14.0% ( 9.4% - 18.6% ) 56.5%
FAM19A4  methylation 104 / 180 57.8% ( 50.6% - 65.0% ) 243 / 328 74.1% ( 69.3% - 78.8% ) 55.0% ( 47.9% - 62.1% ) 23.8% ( 19.1% - 28.5% ) 37.2%
HPV16/18 genotyping 106 / 180 58.9% ( 51.7% - 66.1% ) 191 / 328 58.2% ( 52.9% - 63.6% ) 43.6% ( 37.4% - 49.9% ) 27.9% ( 22.5% - 33.3% ) 47.8%
FAM19A4  methylation and/or cytology 162 / 180 90.0% ( 85.6% - 94.4% ) 145 / 328 44.2% ( 38.8% - 49.6% ) 47.0% ( 41.7% - 52.2% ) 11.0% ( 6.2% - 15.9% ) 67.9%
FAM19A4  methylation and/or HPV16/18 genotyping 141 / 180 78.3% ( 72.3% - 84.4% ) 145 / 328 44.2% ( 38.8% - 49.6% ) 43.5% ( 38.1% - 48.9% ) 11.0% ( 15.3% - 27.1% ) 63.8%
Cytology and/or HPV16/18 genotyping 161 / 180 89.4% ( 85.0% - 93.9% ) 111 / 328 33.8% ( 28.7% - 39.0% ) 42.6% ( 37.6% - 47.6% ) 14.6% ( 8.5% - 20.7% ) 74.4%
Subgroup: women <30 years (n=221)
Cytology 53 / 69 76.8% ( 66.9% - 86.8% ) 88 / 152 57.9% ( 50.0% - 65.7% ) 45.3% ( 36.3% - 54.3% ) 15.4% ( 8.5% - 22.3% ) 52.9%
FAM19A4  methylation 25 / 69 36.2% ( 24.9% - 47.6% ) 127 / 152 83.6% ( 77.7% - 89.4% ) 50.0% ( 36.1% - 63.9% ) 25.7% ( 19.2% - 32.3% ) 22.6%
HPV16/18 genotyping 42 / 69 60.9% ( 49.4% - 72.4% ) 89 / 152 58.6% ( 50.7% - 66.4% ) 40.0% ( 30.6% - 49.4% ) 23.3% ( 15.6% - 31.0% ) 47.5%
FAM19A4  methylation and/or cytology 56 / 69 81.2% ( 71.9% - 90.4% ) 75 / 152 49.3% ( 41.4% - 57.3% ) 42.1% ( 33.7% - 50.5% ) 14.8% ( 7.4% - 22.2% ) 60.2%
FAM19A4  methylation and/or HPV16/18 genotyping 49 / 69 71.0% ( 60.3% - 81.7% ) 76 / 152 50.0% ( 42.1% - 57.9% ) 39.2% ( 30.6% - 47.8% ) 20.8% ( 12.7% - 29.0% ) 56.6%
Cytology and/or HPV16/18 genotyping 60 / 69 87.0% ( 79.0% - 94.9% ) 51 / 152 33.6% ( 26.0% - 41.1% ) 37.3% ( 29.8% - 44.7% ) 15.0% ( 6.0% - 24.0% ) 72.9%
Subgroup: women ≥30 years (n=287)
Cytology 96 / 111 86.5% ( 80.1% - 92.8% ) 102 / 176 58.0% ( 50.7% - 65.2% ) 56.5% ( 49.0% - 63.9% ) 12.8% ( 6.8% - 18.9% ) 59.2%
FAM19A4  methylation 79 / 111 71.2% ( 62.7% - 79.6% ) 116 / 176 65.9% ( 58.9% - 72.9% ) 56.8% ( 48.6% - 65.1% ) 21.6% ( 15.0% - 28.3% ) 48.4%
HPV16/18 genotyping 64 / 111 57.7% ( 48.5% - 66.8% ) 102 / 176 58.0% ( 50.7% - 65.2% ) 46.4% ( 38.1% - 38.1% ) 31.5% ( 24.1% - 61.9% ) 48.1%
FAM19A4  methylation and/or cytology 106 / 111 95.5% ( 91.6% - 99.4% ) 70 / 176 39.8% ( 32.5% - 47.0% ) 50.0% ( 43.3% - 56.7% ) 6.7% ( 1.0% - 12.3% ) 73.9%
FAM19A4  methylation and/or HPV16/18 genotyping 92 / 111 82.9% ( 75.9% - 89.9% ) 69 / 176 39.2% ( 32.0% - 46.4% ) 46.2% ( 39.3% - 53.2% ) 21.6% ( 13.0% - 30.2% ) 69.3%
Cytology and/or HPV16/18 genotyping 101 / 111 91.0% ( 85.7% - 96.3% ) 60 / 176 34.1% ( 27.1% - 41.1% ) 46.5% ( 39.9% - 53.2% ) 14.3% ( 6.1% - 22.5% ) 75.6%
Subgroup: women referred to gynecologist for non-cervix related complaints (n=295)
Cytology 49 / 69 71.0% ( 60.3% - 81.7% ) 156 / 226 69.0% ( 63.0% - 75.1% ) 41.2% ( 32.3% - 50.0% ) 11.4% ( 6.7% - 16.1% ) 40.3%
FAM19A4  methylation 35 / 69 50.7% ( 38.9% - 62.5% ) 173 / 226 76.5% ( 71.0% - 82.1% ) 39.8% ( 29.5% - 50.0% ) 16.4% ( 11.4% - 21.5% ) 29.8%
HPV16/18 genotyping 44 / 69 63.8% ( 52.4% - 75.1% ) 135 / 226 59.7% ( 53.3% - 66.1% ) 32.6% ( 24.7% - 40.5% ) 15.6% ( 10.0% - 21.3% ) 45.8%
FAM19A4  methylation and/or cytology 55 / 69 79.7% ( 70.2% - 89.2% ) 122 / 226 54.0% ( 47.5% - 60.5% ) 34.6% ( 27.2% - 42.0% ) 10.3% ( 5.2% - 15.4% ) 53.9%
FAM19A4  methylation and/or HPV16/18 genotyping 54 / 69 78.3% ( 68.5% - 88.0% ) 108 / 226 47.8% ( 41.3% - 54.3% ) 31.4% ( 24.5% - 38.3% ) 12.2% ( 6.4% - 18.0% ) 58.3%
Cytology and/or HPV16/18 genotyping 58 / 69 84.1% ( 75.4% - 92.7% ) 92 / 226 40.7% ( 34.3% - 47.1% ) 30.2% ( 23.7% - 36.7% ) 10.7% ( 4.7% - 16.6% ) 65.1%
(95%CI)
CIN=cervical intraepithelial neoplasia (grade 2 or 3 or higher); CI=confidence interval; PPV=positive predictive value; 1-NPV=  complemented negative predictive value; n1= number of test positive disease cases; N1= total number of disease cases; n2= 
number of test negative non-disease cases; N2= total number of non-disease cases; *based on % marker positivity
n1 / N1 (95%CI) n2 / N2 (95%CI) (95% CI)
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Table 3. 
Table 3A: Age as a covariate of the performance of FAM19A4 methylation analysis. The odds ratios represent the odds 
of a positive FAM19A4 result in women aged ≥30 relative to women aged <30 (stratified by histological endpoint).  
p # p #
≥CIN3 7.571 ( 2.611 - 21.956 ) 0.000 7.061 ( 2.197 - 22.698 ) 0.001
<CIN3 2.717 ( 1.727 - 4.274 ) 0.000 2.732 ( 1.701 - 4.405 ) 0.000
≥CIN2 4.345 ( 2.291 - 8.240 ) 0.000 5.107 ( 2.390 - 10.915 ) 0.000
<CIN2 2.625 ( 1.546 - 4.464 ) 0.000 2.551 ( 1.477 - 4.386 ) 0.001
Covariate: age (0 = <30 years, 1 = ≥30 years)
Response variable: FAM19A4 methylation analysis  (0 = negative, 1 = positive)
Unadjusted analysis Adjusted analysis*
odds ratio (95% CI) odds ratio (95% CI)
Inclusion 
criterium
*adjusted for referral reason of patient and sampling method of cervical scrape; # p-value obtained by logistic regression; 
CIN = cervical intraepithelial neoplasia (grade 2 or 3 or higher); CI = confidence interval  
Table 3B: Referral reason as a covariate of  the performance of cytology. The odds ratios represent the odds of a positive 
cytology result in women referred to the gynecologist because of abnormal cytology relative to women referred for non-
cervix-related complaints (stratified by histological endpoint). 
p # p #
≥CIN3 1.667 ( 0.490 - 5.672 ) 0.414 5.346 ( 0.533 - 53.590 ) 0.154
<CIN3 5.291 ( 3.378 - 8.264 ) 0.000 7.299 ( 3.356 - 15.873 ) 0.000
≥CIN2 3.711 ( 1.649 - 8.351 ) 0.002 5.507 ( 1.371 - 22.120 ) 0.016
<CIN2 4.464 ( 2.703 - 7.353 ) 0.000 6.024 ( 2.404 - 15.152 ) 0.000
* adjusted for age of patient and sampling method of cervical scrape; # p-value obtained by logistic regression;                   
CIN = cervical intraepithelial neoplasia (grade 2 or 3 or higher); CI = confidence interval
odds ratio (95% CI) odds ratio (95% CI)
Covariate: referral reason to gynecologist (0 = non-cervix-related complaints, 1 = abnormal cytology)
Response variable: cytology (0 = negative, 1 = positive)
Inclusion 
criterium
Unadjusted analysis Adjusted analysis*
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FIGURES 
 
Figure 1. Overview of study population. hrHPV = high-risk human papillomavirus, ntd = not to determine, LLETZ = 
large loop excision of the transformation zone, UE = uterus expiration 
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Figure 2. Sensitivities and specificities of different markers for ≥CIN3 detection in hrHPV-positive women. Forest 
plots showing the relative sensitivity and specificity of the different markers compared to cytology are presented in the 
total study population and the subgroup of women aged ≥30 years.  
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Figure 3. Sensitivities and specificities of different markers for ≥CIN2 detection in hrHPV-positive women. Forest 
plots showing the relative sensitivity and specificity of the different markers compared to cytology are presented in the 
total study population and the subgroup of women aged ≥30 years. 
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Supplementary Figure 1. ≥CIN3 and ≥CIN2 sensitivities and specificities of different triage tests for hrHPV-positive women 
aged ≥25 years. Forest plots showing the relative sensitivity and specificity of the different triage tools compared to cytology are 
presented. 
 
25 
 
